Ocular manifestations of COVID-19: facts and figures from a tertiary care center

Nissar Shaikh, Huda Al Mahdi, Anant Pai, Ankush Pathare, Ahmad A. Abujaber, Ashwin Dsilva, Mahmood Al-Jabry, Kumran Subramanian, Saju Thomas, Ahmed S. Mohamed, Shahzad Anjum, Abdulqadir J. Nashwan, Mohammad Al Wraidat, and Mohamad Y. Khatib

Surgical Intensive Care Department, Hamad General Hospital (HGH), Hamad Medical Corporation (HMC), Doha, Qatar; Ophthalmology Department, Hamad General Hospital (HGH), Hamad Medical Corporation (HMC), Doha, Qatar; Accident and Emergency Department, Hazm Mebaireek General Hospital (HMGH), Hamad Medical Corporation (HMC), Doha, Qatar; Critical Care Department, Hazm Mebaireek General Hospital (HMGH), Hamad Medical Corporation (HMC), Doha, Qatar

ABSTRACT
Introduction: COVID-19 patients presenting with ocular manifestations are from 0.8% to 32% of patients seen in the ED. The available literature is scarce regarding COVID-19 patients presenting with ocular manifestations from the Middle Eastern region.

Purpose: This study aims to report the incidence of ocular signs and symptoms in COVID-19 patients and find any correlation between the occurrence of ocular manifestations and patients' comorbidities.

Methods: All patients having the primary diagnosis of COVID-19 infection and concurrent ocular manifestations on admission to our tertiary COVID-19 health care centre were included in the study. The patient's demographic data, comorbidities, and type of ocular manifestations were recorded from the patients' health records retrospectively.

Results: In our study, 39 (7.8%) patients presented with ocular manifestations. The majority of COVID-19 patients were male, and 200 (20%) patients had a history of other comorbidities. The majority of our patients had hyperaemia (13 [33.3%]), followed by eye pain (9 [23.1%]), epiphora (8 [20.5%]), burning sensation (4 [10.3%]), and photophobia (2 [5.1%]) patients. There was no statistically significant difference in the occurrence of ocular manifestations and patients' gender or comorbidities (p > .05).

Conclusion: The occurrence of ocular manifestations was lower compared to the present literature. There was no significant association between the occurrence of ocular manifestations and the patient's gender or comorbidities.

Introduction
COVID-19 pneumonia was initially reported in China in late 2019. Despite aggressive restrictive and preventive measures, it quickly spread to become a global pandemic, greatly impacting peoples' lives, finances, and the world economy [1]. Since COVID-19 pneumonia is a potentially life-threatening condition, the primary focus of the research has naturally been on the respiratory system. But the COVID-19 infection can involve several other organs of the body, and there is growing evidence of its impact on eyes and vision. Ocular manifestations in COVID-19 patients can vary.

Significant restrictions and reduction may hinder the documentation of ocular symptoms and signs in patients with COVID-19 infection in ophthalmic services during the ongoing pandemic [2]. In addition, it is understandable that the care and observations of the life-threatening conditions take precedence over the ocular conditions and their clinical documentation [2].

The prevalence of ocular symptoms and signs in COVID-19 patients can range from <1% to >30% [3,4]. Initial reports from China reported around 0.8% of all COVID-19 patients had signs and symptoms of eye involvement. The various ophthalmic features in COVID-19 patients described in the literature include burning eyes, foreign body sensation in eyes, photophobia, clear watery discharge, eyelid edema, conjunctival hyperaemia, conjunctival injection, pseudomembranous and haemorrhagic conjunctivitis.
follicular kerato-conjunctivitis and corneal sub-epithelial infiltrates [5,6]. It is also been reported that, rarely, ophthalmic features may represent the first clinical presentation in patients with COVID-19 infection [5,6]. More recent data suggest that ocular manifestations are higher than initially reported and are up to 11.03% in some studies [7].

There are no publications or available literature from the Middle East region on this topic. Therefore, the purpose of our study was to report the occurrence of ocular manifestations and the impact of comorbidities in COVID-19 patients in a tertiary care setup.

Methods

After obtaining permission from the medical research centre of our hospital, all patients presented from March to May 2021 with ocular manifestation with COVID-19 infections confirmed by throat polymerase chain reaction (PCR) were included retrospectively in this study. All patients’ demographic data, comorbidities, details of ocular symptoms were recorded from the patients’ electronic files retrospectively.

Data were entered and analyzed using IBM SPSS version 23. Descriptive statistics in the form of mean and standard deviation were performed for interval variables. The frequency with percentages was calculated for categorical variables. Chi-square tests were performed to determine the association between categorical variables. Student’s t-test was performed to determine statistically significant mean differences between interval variables, the p-value of ≤ .05 (two-tailed) was considered statistically significant.

Results

During the study period, a total of 500 patients were admitted with COVID-19 pneumonia to our tertiary care centre. Only 39 (7.8%) patients had ocular manifestations at the hospital’s presentation time (Table 1). The majority of patients (463 [92.6%]) were male. 200 (40%) patients had various comorbidities, including hypertension, diabetes mellitus, coronary artery disease, rheumatic arthritis, or cancer. CT value was less than 30 in 94.2% of patients. The majority of patients had normal leucocytes and CRP (C-reactive protein) 477 (95.4%) and 263 (52.6%), respectively (Table 1).

Table 1. Patients’ demographics.

| Variable                  | Number | Percentage |
|---------------------------|--------|------------|
| Gender                    |        |            |
| Male                      | 463    | 92.6       |
| Female                    | 37     | 7.4        |
| Ocular manifestations     |        |            |
| Yes                       | 39     | 7.8        |
| No                        | 461    | 92.2       |
| Comorbidities             |        |            |
| Yes                       | 200    | 40         |
| No                        | 300    | 60         |
| CT value                  |        |            |
| ≤30                       | 471    | 94.2       |
| >30                       | 29     | 5.8        |
| WBC (white blood cell)    |        |            |
| ≤11                       | 477    | 95.4       |
| >11                       | 23     | 4.6        |
| CRP (C-reactive protein)  |        |            |
| ≤15                       | 263    | 52.6       |
| 16–50                     | 133    | 26.6       |
| 51–100                    | 56     | 11.2       |
| >100                      | 48     | 9.6        |

Table 2 is showing the details of ocular manifestations in COVID-19 patients. The majority of our patients had hyperaemia (13 [33.3%]), followed by eye pain (9 [23.1%]), epiphora (8 [20.5%]), burning sensations (4 [10.3%]), and photophobia (2 [5.1%]) patients. Table 4 shows the comparison of ocular manifestations with other variables and their significance. There was no significant relationship between patients’ gender and occurrence of ocular manifestations (p = .43), comorbidities (p = .4), or CT value (p = .31).

Discussion

COVID-19 infection can involve all body organs and systems. Any part of the eye and ocular adnexa can get involved in COVID-19 patients. Ocular manifestations in these patients can either occur due to direct implantation of viral load in conjunctival mucosa [8]
or through the haematogenous route to the posterior segment [9]. In our COVID-19 patients, 7.8% had symptoms related to the eyes. Literature mentions the incidence of ocular manifestations from 0.8% to 11.03% depending on the institution and area [1,2]. Sen et al. reported a higher incidence of up to 32% of COVID-19 patients [8].

Almazroa and colleagues, in their review, also reported 32% of the COVID-19 patients presented with ocular signs and symptoms [10]. Agrawal et al., in their review, reported that follicular conjunctivitis occurred in 7%, chemosis in 4.4%, conjunctival congestion in 10.89% of patients [11]. Wu et al. and Hang et al. reported equal percentages of ocular signs, mainly redness, dryness, ocular pain, foreign body sensation, discharge, itching, and follicular conjunctivitis [3,12].

In our patients, the most frequent ocular manifestation was conjunctival hyperaemia (33.3%), followed by eye pain (9.231%), epiphora (20.5%), burning sensation (10.3%), and less frequent were conjunctivitis and photophobia in 5.1% of patients.

Zhang et al. reported conjunctivitis to be the most frequent ocular manifestation in their population [13]. Tostman et al. reported ocular pain as the most frequent ocular symptom in COVID-19 patients [14]. Xu et al. reported itching as the prime ocular symptom, whereas Karimi et al. described foreign body sensation as the most frequent symptom in COVID-19 patients [9,15].

Significant changes occur in the immune and coagulation systems in COVID-19 patients. It is also possible that the virus can spread to the eye by haematogenous route, thus involving the eyes’ posterior segment (i.e. retina, choroid, and vitreous) though it is not known to be very common [16]. In a small cohort of asymptomatic COVID-19 positive patients, a group of authors has reported few retinal lesions in the form of cotton-wool-spot-like lesions and retinal microhemorrhages in 33% of patients [17]. There are also many case reports and publications on ophthalmic manifestations in COVID-19 patients and on the association of COVID-19 with different parts of the eye and its adnexa starting from the conjunctiva, episcleral tissue, sclera, extraocular muscles, orbit, posterior segment, optic nerve, and the visual pathways [18–20]. This study has a few limitations. Ophthalmologists were not involved in a comprehensive evaluation of ophthalmic symptoms of these patients, this study being retrospective in nature. The other important limitation of our study is the unavailability of data on the posterior segment and the retinal involvement.

To the best of the authors’ knowledge, this is the first study showing no correlation between patients’ gender, comorbidities, and occurrence of ocular manifestations in COVID-19 patients.

**Conclusion**

The ocular manifestations were in the lower range in our patients compared to the literature. The patient’s gender and comorbidities did not correlate with the occurrence of ocular signs and symptoms. These patients did not necessarily have fever or leukocytosis upon presentation. Early detection and proper use of personal protective equipment could aid in the prevention of COVID-19 transmission.

**Ethics approval and consent to participate**

The project has been approved (exempted) by the Medical Research Centre (MRC) IRB in Hamad Medical Corporation (MRC-01-21-441). The study has been conducted in accordance with the ethical standards noted in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. No consents were obtained due to the retrospective nature of the study.
Authors’ contributions
NSH: Conceptualization; AAA: Formal Analysis; NSH, HAM, API, ANP, AAA, ASD, MAJ, KRS, ASM, SHA, AJN, MAW, MYK: Data Curation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing.

Acknowledgements
The project has been funded by the medical research center at Hamad Medical Corporation.

Disclosure statement
The authors declare that they have no competing interests.

Funding
This study was funded by the Medical Research Centre at Hamad Medical Corporation [MRC-01-21-441].

ORCID
Ahmad A. Abujaber http://orcid.org/0000-0002-8704-4991
Ahmed S. Mohmed http://orcid.org/0000-0002-2107-5357
Abdulqadir J. Nashwan http://orcid.org/0000-0003-4845-4119

Data availability statement
All generated data is included in this published article. All authors read and approved the final manuscript.

References
[1] Cascella M, Rajnik M, Aleem A, et al. Features, evaluation, and treatment of coronavirus (COVID-19). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
[2] Deiner MS, Seitzman GD, McLeod SD, et al. Ocular signs of COVID-19 suggested by internet search term patterns worldwide. Ophthalmology. 2021;128(1):167–169.
[3] Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei province, China. JAMA Ophthalmol. 2020;138(5):575–578.
[4] Zhou Y, Duan C, Zeng Y, et al. Ocular findings and proportion with conjunctival SARS-CoV-2 in COVID-19 patients. Ophthalmology. 2020;127(7):982–983.
[5] Daruich A, Martin D, Bremond-Gignac D. Unilateral conjunctivitis as first presentation of coronavirus disease 2019 (COVID-19): a telemedicine diagnosis. J Fr Ophtalmol. 2020;43(5):e167–e168.
[6] Khavandi S, Tabibzadeh E, Naderan M, et al. Coronavirus disease-19 (COVID-19) presenting as conjunctivitis: atypically high-risk during a pandemic. Cont Lens Anterior Eye. 2020;43(3):211–212.
[7] Nasiri N, Sharifi H, Bazrafshan A, et al. Ocular manifestations of COVID-19: a systematic review and meta-analysis. J Ophthalmic Vis Res. 2021;16(1):103–112.
[8] Sen M, Honavar SG, Sharma N, et al. COVID-19 and eye: a review of ophthalmic manifestations of COVID-19. Indian J Ophthalmol. 2021;69(3):488–509.
[9] Xu L, Zhang X, Song W, et al. Conjunctival polymerase chain reaction-tests of 2019 novel coronavirus in patients in Shenyang, China. medRxiv. 2020. https://doi.org/10.1101/2020.02.23.20024935
[10] Almazroa A, Alamri S, Alabdulkader B, et al. Ocular transmission and manifestation for coronavirus disease: a systematic review. Int Health. 2021. https://doi.org/10.1093/inthealth/ihab028
[11] Aggarwal K, Agarwal A, Jaiswal N, et al. Ocular surface manifestations of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. PLoS One. 2020;15(11):e0241661.
[12] Hong N, Yu W, Xia J, et al. Evaluation of ocular symptoms and tropism of SARS-CoV-2 in patients confirmed with COVID-19. Acta Ophthalmol. 2020;98(5):e649–e655.
[13] Zhang X, Chen X, Chen L, et al. The evidence of SARS-CoV-2 infection on ocular surface. Amsterdam (The Netherlands): Elsevier; 2020.
[14] Tostmann A, Bradley J, Bousema T, et al. Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, The Netherlands, march 2020. Eurosurveillance. 2020;25(16):2000508.
[15] Karimi S, Arabi A, Shahrazi T, et al. Detection of severe acute respiratory syndrome coronavirus-2 in the tears of patients with coronavirus disease 2019. Eye. 2020;34(7):1220–1223.
[16] Pirraglia MP, Ceccarelli G, Cerini A, et al. Retinal involvement and ocular findings in COVID-19 pneumonia patients. Sci Rep. 2020;10(1):17419.
[17] Marinho PM, Marcos AA, Romano AC, et al. Retinal findings in patients with COVID-19. The Lancet. 2020;395(10237):1610.
[18] De Salvo G, Meduri A, Vaz-Pereira S, et al. An uncommon cold of the retina. Surv Ophthalm. 2021. https://doi.org/10.1016/j.survophthal.2021.08.006
[19] Freni F, Meduri A, Gazia F, et al. Symptomatology in head and neck district in coronavirus disease (COVID-19): a possible neuroinvasive action of SARS-CoV-2. Am J Otolaryngol. 2020;41(5):102612.
[20] Meduri A, Oliverio GW, Mancuso G, et al. Ocular surface manifestation of COVID-19 and tear film analysis. Sci Rep. 2020;10(1):20178.